Latest Headlines

Latest Headlines

Valeant gets manufacturing in Middle East with deal for Amoun

With its $800 million deal for Amoun Pharmaceutical, Valeant picks up what the Egyptian drugmaker says is one of the largest and most up-to-date pharmaceutical facilities in Africa and the Middle East.

AMRI bets $174M on manufacturing with latest buyout

Contract drugmaker AMRI paid $174 million for a Spanish manufacturing operation, part of the company's long-term plan to dial up its focus on production.

Stryker to buy Turkish partner in its second hospital bed acquisition in 2015

Stryker has only disclosed plans for two acquisitions this year--both for private, international, hospital bed makers. The latest is an all-cash deal for Turkish hospital bed, stretcher and patient room furniture and accessory maker Muka, which is headquartered in Kayseri, Turkey.

Valeant grabs a Middle Eastern foothold with $800M pact for Egypt's Amoun

Last month, reports said Valeant was stepping up talks on a deal for one of Egypt's largest drugmakers. And now, it's pulled the trigger.

AMRI shells out $174M for a Spanish drugmaker

Contract drug developer AMRI bought Spain's Gadea Pharmaceutical for $174 million, picking up a company focused on the manufacture of active ingredients and finished treatments.

Pharma M&A shoots up to $159B for first half, but prices could dampen the mood

Think last year was an M&A record-breaker in biopharma? 2015 is on track to top it, a new report says.

Celgene chief Bob Hugin isn't done betting on 'binary' biotech deals

By all accounts, the bidding war for Receptos was intense. But for Celgene CEO Bob Hugin and his go-to deals chief George Golumbeski, strategically this was exactly the right time to clinch a $7.2 billion buyout deal for the biotech and its lead drug ozanimod. And after they add this latest late-stage program to the pipeline, there are still more deals to be done.

UPDATED: Celgene shells out $7.2B for Receptos in a big bet on autoimmune disease

Celgene is trading $7.2 billion in cash for Receptos and its Phase III autoimmune treatment, building on some recent success in the field.

Playing catch-up on Big Biotech goal, Shire broadens M&A focus

Shire's $54 billion tie-up with AbbVie--and the subsequent cancellation of that deal--shook up employees and stalled CEO Flemming Ornskov's plans to transform the company into a biotech the likes of giants Gilead, Biogen and Celgene. It also took the Dublin drugmaker off course in one of its other endeavors: dealmaking.

UPDATED: Consumer groups urge FTC to take Mylan's side in Teva deal fight

Mylan is dead set against a buyout bid from generics rival Teva Pharmaceutical Industries. But some U.S. consumer groups are spooked by the very talk of a deal, and they're lobbying the Federal Trade Commission against it.